This is a pivotal, 12-month, randomized, sham controlled, parallel group, multicenter, double blind study with an allocation ratio of 1:1. The study population is children between the ages 6 to 17 years, with mild to moderate persistent asthma. The purpose of the study is to determine whether the CREON2000A, an environmental control device, will decrease asthma severity, as measured by the Composite Asthma Severity Index (CASI), in children with mild to moderate persistent allergic asthma over a twelve month period.
The pilot study (Protocol #PA-01-052; Health Effects of CREON2000 in Asthmatic Children. IB ID# GI 1001) offered preliminary evidence that the CREON2000A system may be beneficial in asthma. This study is a follow-up, using children, aged 6 to 17 with mild to moderate persistent asthma, as the subjects of the study. Children are usually treated with fewer controller medications and have fewer confounding co-morbidities making it more likely to detect a therapeutic benefit from an environmental intervention. The study will involve 4 study site visits, 2 home visits, and 7 phone calls. Adjustment of asthma therapy by the site clinician will occur at baseline (Visit 1) and at each follow-up office visit after Visit 1 using a modified algorithm based on the National Asthma Education and Prevention Program Expert Panel Report 3 (NAEPP EPR3) guidelines. Enrollment will be over 18 months. The study duration for each subject will be 12 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
83
Advanced Research Institute of Miami, LLC
Homestead, Florida, United States
Allergy & Asthma Associates
Lexington, Kentucky, United States
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio, United States
Bernstein Clinical Research Center, LLC
Change in CASI Score
Difference between study arms in the change in asthma severity as measured by the Composite Asthma Severity Index (CASI) from Baseline (Visit 1) to the 12-month follow up office visit
Time frame: Baseline and 12 months
Change in Forced Expiratory Volume (FEV1)
• in the mean change in FEV1 (% predicted) from Baseline (Visit 1) to 12-month follow up office visit
Time frame: Baseline and 12 months
Mean change in number of day time symptom scores
• in the mean change in number of day time symptom scores from Baseline (Visit 1) to the 4, 8 and 12-month follow up office visits
Time frame: Baseline, 4, 8 and12 months
Mean change in number of night time symptoms
• in the mean change in number of night time symptom scores from Baseline (Visit 1) to the 4, 8 and 12-month follow up office visits
Time frame: Baseline, 4, 8 and 12 months
Mean change in the number of daily puffs/inhalations of short-acting beta-agonist (SABA) rescue medication
• in the mean change in the number of daily puffs/inhalations of short-acting beta-agonist rescue medication taken over 14 days prior to each evaluation, from Baseline (Visit 1) to 4, 8 and 12 month follow up office visits
Time frame: Baseline, 4, 8 and 12 months
Mean Change in CASI
• in the mean change in CASI from Baseline (Visit 1) to 4- and 8- and 12-month follow up office visits
Time frame: Baseline, 4, 8 and 12 months
Mean change in daily does of inhaled glucocorticoids taken (µg/day)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cincinnati, Ohio, United States
Columbus Nationwide Children's Hospital
Columbus, Ohio, United States
Ohio Pediatric Research Assn.
Dayton, Ohio, United States
Toledo Institute of Clinical Research
Toledo, Ohio, United States
Great Lakes Medical Research, LLC
Willoughby, Ohio, United States
• in the mean change in daily dose of inhaled glucocorticoids taken (µg/day) by participants from Baseline (Visit 1) to 4, 8 and 12 months follow up office visits.
Time frame: Baseline 4, 8 and 12 months
Mean change in the percentage of patients with an asthma exacerbation
• in the mean change in the percentage of patients with an asthma exacerbation during the period from baseline (Visit 1) to the 12 month follow up office visit
Time frame: Baseline and12 months